Research programme: glycan-binding biopharmaceuticals - ProtAffin Biotechnologie

Drug Profile

Research programme: glycan-binding biopharmaceuticals - ProtAffin Biotechnologie

Alternative Names: MCP-1 programme - ProtAffin; Oncology programme - ProtAffin; PA508; SDF-1α programme - ProtAffin

Latest Information Update: 04 Sep 2013

Price : $50

At a glance

  • Originator ProtAffin Biotechnologie
  • Class Proteins
  • Mechanism of Action Glycosaminoglycan inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Coronary artery restenosis; Diabetic retinopathy; Fibrosis; Multiple sclerosis; Myocardial infarction; Uveitis

Most Recent Events

  • 31 Jul 2013 ProtAffin Biotechnologie has ceased operations
  • 31 Jul 2013 Discontinued - Preclinical for Coronary artery restenosis in Austria (Parenteral)
  • 31 Jul 2013 Discontinued - Preclinical for Multiple sclerosis in Austria (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top